查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1871894

非藥物調變器市場預測至2032年：按作用方式、作用機制、供應類型、分銷管道、應用、最終用戶和地區分類的全球分析

Non-Pharmacologic Modulators Market Forecasts to 2032 - Global Analysis By Modality, Mechanism of Action, Delivery Mode, Distribution Channel, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2025 年，全球非藥物調變器市場規模將達到 17.8 億美元，到 2032 年將達到 25.5 億美元，預測期內複合年成長率為 5.2%。

非藥物調變器是指無需使用藥物即可影響生理或心理過程的治療性介入。這些方法包括認知行為療法、神經調控、物理復健、正念療法和生活方式調整。它們常用於疼痛管理、心理健康和慢性病護理，旨在透過增強人體自身的調節機制來最佳化患者的治療效果。非藥物調變器因其副作用小、療效持久以及能夠補充或減少對藥物治療的依賴性而備受青睞。

人們越來越傾向於選擇非侵入性治療

由於副作用較少且患者依從性更高，神經調控、認知行為療法 (CBT) 和生物回饋療法等療法正受到患者和醫療專業人員的青睞。這些治療方法能夠針對性地緩解症狀，並且避免了藥物相關的全身性風險。此外，穿戴式科技和數位平台的進步也使得這些療法更加普及和個人化。

缺乏長期療效數據

許多治療方法缺乏標準化的臨床通訊協定，導致難以比較不同族群和疾病的治療效果。這種循證數據的缺乏會阻礙監管部門的核准和報銷，從而減緩市場滲透。此外，傳統醫療機構的質疑態度也會限制這些療法融入主流治療體系。如果沒有強力的臨床試驗和上市後監測，這些治療方法的擴充性和可靠性仍然有限。

老化社會與神經退化性疾病護理

阿茲海默症、帕金森氏症和輕度認知障礙等疾病推動了對無需藥物負擔即可支持神經可塑性和自主神經調節的治療方法的需求。腦機介面、引導式神經回饋和居家認知訓練工具等創新技術正在拓展老年護理的治療選擇。此外，醫療保健系統正在投資於旨在降低多重用藥風險和提高老年人生活品質的非藥物干預措施，這為市場擴張創造了有利條件。

來自藥物和混合療法的競爭

生物製藥、標靶治療和聯合療法因其快速緩解症狀和較高的臨床接受度，往往分散人們對其他療法的關注。此外，製藥公司受益於成熟的分銷網路和報銷體系，使得非藥物療法難以獲得同等的市場佔有率。隨著混合模式將數位療法與藥物療法結合，獨立調節劑必須透過療效、成本效益和病人參與來脫穎而出，保持其市場地位。

新冠疫情的影響：

新冠疫情加速了人們對遠端醫療和非侵入性醫療解決方案的興趣，為非藥物調變器市場帶來了利好。封鎖措施和醫療機構的緊張狀況促使患者尋求居家治療，以緩解壓力、疼痛和神經系統疾病。隨著人們更加重視在臨床環境之外維護心理健康和管理慢性疾病，數位認知行為療法（CBT）平台、穿戴式神經調節設備和支持遠端醫療的生物回饋療法工具的使用率顯著提高。然而，供應鏈中斷和臨床試驗的延遲暫時阻礙了產品開發和監管核准。

預計在預測期內，認知行為療法（CBT）細分市場將佔據最大的市場佔有率。

由於認知行為療法 (CBT) 應用廣泛，涵蓋心理健康、疼痛管理和行為障礙等領域，預計在預測期內，CBT 將佔據最大的市場佔有率。 CBT 易於適應數位化平台，且以實證醫學為基礎，因此深受臨床醫生和患者的青睞。該領域受益於人們對心理健康的日益關注、數位療法資金的增加以及數位療法在基層醫療機構中的應用。 CBT 的模組化設計使其能夠制定個人化的治療方案，從而提高其在不同患者群體中的有效性和擴充性。

預計在預測期內，自主神經調節領域將呈現最高的複合年成長率。

預計在預測期內，自主神經系統調節領域將達到最高成長率，這主要得益於其在壓力相關疾病、心血管健康和神經退化性疾病管理中的重要角色。迷走神經刺激、心率變異性訓練和引導式呼吸等技術因其恢復生理平衡的能力而備受關注。穿戴式生物感測器和人工智慧驅動的回饋系統的創新也為該領域提供了支持，這些創新能夠實現即時監測和自適應治療。

佔比最大的地區：

由於北美擁有完善的醫療保健基礎設施、對非藥物療法的高度認知以及有利的報銷政策，預計該地區將在預測期內佔據最大的市場佔有率。該地區匯聚了許多數位療法和神經調控領域的主要企業，推動創新和早期應用。政府促進心理健康和慢性病管理的措施也進一步刺激了市場需求。此外，將非藥物調變器整合到遠端醫療平台和企業健康計畫中，正在擴大其在都市區和農村地區的覆蓋範圍。

複合年成長率最高的地區：

在預測期內，北美預計將實現最高的複合年成長率，這主要得益於對研究、技術和醫療數位化的持續投資。該地區在心理健康、老年護理和預防醫學方面採取的積極主動的態度，為非侵入性治療方法創造了有利條件。學術機構、Start-Ups和醫療服務提供者之間的合作正在加速產品開發和臨床檢驗。在消費者對個人化和整體護理需求不斷成長的推動下，北美仍然是市場擴張的活力中心。

關於免費客製化服務：

購買此報告的客戶可享有以下免費自訂選項之一：

  • 公司概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 主要參與者（最多3家公司）的SWOT分析
  • 區域細分
    • 根據客戶興趣對主要國家進行市場估算、預測和複合年成長率分析（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據主要參與者的產品系列、地理覆蓋範圍和策略聯盟基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 原始研究資料
    • 次級研究資訊來源
    • 先決條件

第3章 市場趨勢分析

  • 介紹
  • 促進要素
  • 抑制因素
  • 機會
  • 威脅
  • 應用分析
  • 終端用戶分析
  • 新興市場
  • 新冠疫情的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球非藥物調變器市場（依治療方式分類）

  • 介紹
  • 認知行為治療（CBT）
  • 正念減壓療法（MBSR）
  • 生物回饋療法
  • 神經回饋
  • 經顱磁刺激（TMS）
  • 其他方式

6. 全球非藥物調變器市場依作用機制分類

  • 介紹
  • 增強的神經可塑性
  • 自主神經系統的調節
  • 荷爾蒙調節
  • 免疫系統調節
  • 阻斷疼痛通路
  • 其他機制

7. 全球非藥物調變器市場（依供應類型分類）

  • 介紹
  • 面對面治療
  • 數位療法
  • 穿戴式裝置
  • 遠端監控平台
  • 其他供應形式

8. 全球非藥物調變器市場（依分銷管道分類）

  • 介紹
  • 直銷
  • 經銷商
  • 線上平台
  • 其他頻道

9. 全球非藥物調變器市場（按應用分類）

  • 介紹
  • 慢性疼痛管理
  • 精神疾病
  • 神經復健
  • 睡眠障礙
  • 心血管調節
  • 其他應用

10. 全球非藥物調變器市場（依最終用戶分類）

  • 介紹
  • 醫院
  • 專科診所
  • 復健中心
  • 居家照護機構
  • 學術研究機構
  • 其他最終用戶

11. 全球非藥物調變器市場（按地區分類）

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 亞太其他地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第12章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與併購
  • 新產品上市
  • 業務拓展
  • 其他關鍵策略

第13章：企業概況

  • Neuroelectrics
  • Flow Neuroscience
  • Happify Health
  • Pear Therapeutics
  • Fisher Wallace Laboratories
  • NeuroSky
  • MindMaze
  • Omada Health
  • Better Therapeutics
  • BehaVR
  • Neurovalens
  • NeuroSigma
  • Cognifisense
  • NeuroTherapeutics Pharma
  • NeuroMetrix
  • Theranica
Product Code: SMRC32264

According to Stratistics MRC, the Global Non-Pharmacologic Modulators Market is accounted for $1.78 billion in 2025 and is expected to reach $2.55 billion by 2032 growing at a CAGR of 5.2% during the forecast period. Non-pharmacologic modulators are therapeutic interventions that influence physiological or psychological processes without the use of pharmaceutical agents. These approaches include techniques such as cognitive-behavioral therapy, neuromodulation, physical rehabilitation, mindfulness, and lifestyle modifications. Often employed in pain management, mental health, and chronic disease care, they aim to optimize patient outcomes by enhancing the body's natural regulatory mechanisms. Non-pharmacologic modulators are valued for their minimal side effects, long-term benefits, and ability to complement or reduce reliance on medication-based treatments.

Market Dynamics:

Driver:

Growing preference for non-invasive treatments

Patients and clinicians alike are gravitating toward therapies such as neuromodulation, cognitive behavioral therapy (CBT), and biofeedback due to their reduced side-effect profiles and improved patient compliance. These modalities offer targeted symptom relief without the systemic risks associated with pharmaceuticals. Moreover, advancements in wearable technologies and digital platforms are enhancing the accessibility and personalization of these treatments.

Restraint:

Limited long-term efficacy data

Many interventions lack standardized clinical protocols, making it difficult to compare outcomes across populations and conditions. This gap in evidence-based data can hinder regulatory approvals and payer reimbursement, slowing market penetration. Additionally, skepticism among traditional healthcare providers may limit integration into mainstream treatment pathways. Without robust clinical trials and post-market surveillance, scalability and trust in these modalities remain constrained.

Opportunity:

Aging population and neurodegenerative care

Conditions such as Alzheimer's, Parkinson's, and mild cognitive impairment are driving demand for therapies that support neuroplasticity and autonomic regulation without pharmacologic burden. Innovations in brain-computer interfaces, guided neurofeedback, and home-based cognitive training tools are expanding therapeutic options for geriatric care. Furthermore, healthcare systems are investing in non-drug interventions to reduce polypharmacy risks and improve quality of life among older adults, creating fertile ground for market expansion.

Threat:

Competition from pharmacologic and hybrid therapies

Biologics, targeted therapies, and combination approaches often offer faster symptom relief or broader clinical acceptance, drawing attention away from alternative modalities. Additionally, pharmaceutical companies benefit from established distribution networks and reimbursement frameworks, making it harder for non-drug solutions to gain comparable traction. As hybrid models integrate digital therapeutics with pharmacologic regimens, standalone modulators must differentiate through efficacy, cost-effectiveness, and patient engagement to maintain relevance.

Covid-19 Impact:

The COVID-19 pandemic accelerated interest in remote and non-invasive healthcare solutions, benefiting the non-pharmacologic modulators market. Lockdowns and overwhelmed healthcare facilities prompted patients to seek home-based therapies for stress, pain, and neurological conditions. Digital CBT platforms, wearable neuromodulators, and telehealth-enabled biofeedback tools saw increased adoption as individuals prioritized mental well-being and chronic disease management outside clinical settings. However, supply chain disruptions and delayed clinical trials temporarily hindered product development and regulatory approvals.

The cognitive behavioral therapy (CBT) segment is expected to be the largest during the forecast period

The cognitive behavioral therapy (CBT) segment is expected to account for the largest market share during the forecast period due to its widespread application across mental health, pain management, and behavioral disorders. CBT's adaptability to digital platforms and its evidence-based framework make it a preferred choice among clinicians and patients. The segment benefits from growing awareness of mental health, increased funding for digital therapeutics, and integration into primary care settings. CBT's modular design allows for personalized treatment plans, enhancing its effectiveness and scalability across diverse populations.

The autonomic nervous system regulation segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the autonomic nervous system regulation segment is predicted to witness the highest growth rate driven by its role in managing stress-related disorders, cardiovascular health, and neurodegenerative conditions. Techniques such as vagus nerve stimulation, heart rate variability training, and guided breathing exercises are gaining traction for their ability to restore physiological balance. The segment is supported by innovations in wearable biosensors and AI-driven feedback systems that enable real-time monitoring and adaptive therapy.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share supported by robust healthcare infrastructure, high awareness of non-drug therapies, and favorable reimbursement policies. The region hosts several key players in digital therapeutics and neuromodulation, fostering innovation and early adoption. Government initiatives promoting mental health and chronic disease management further bolster demand. Additionally, the integration of non-pharmacologic modulators into telehealth platforms and employer wellness programs is expanding their reach across urban and rural populations.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR driven by continuous investment in research, technology, and healthcare digitization. The region's proactive stance on mental health, aging care, and preventive medicine is creating fertile ground for non-invasive therapies. Collaborations between academic institutions, startups, and healthcare providers are accelerating product development and clinical validation. As consumer demand for personalized and holistic care grows, North America remains a dynamic hub for market expansion.

Key players in the market

Some of the key players in Non-Pharmacologic Modulators Market include Neuroelectrics, Flow Neuroscience, Happify Health, Pear Therapeutics, Fisher Wallace Laboratories, NeuroSky, MindMaze, Omada Health, Better Therapeutics, BehaVR, Neurovalens, NeuroSigma, Cognifisense, NeuroTherapeutics Pharma, NeuroMetrix, and Theranica.

Key Developments:

In September 2025, NeuroMetrix shows aprivacy statement / site update and maintains an investor/SEC filings area with 2025 filings indicating corporate/IR activity in 2025. This is a site / regulatory-document update rather than a product launch, but it is a verifiable 2025 entry on the company's investor/privacy pages.

In July 2025, Neuroelectrics sponsored and promoted Workshop 7 ("The Varieties of BCI Brain Computer Interfaces") at The Science of Consciousness (TSC) Barcelona conference, highlighting academic and industry talks supported by the company.

In April 2025, Neuroelectrics announced a breakthrough in depression treatment" tied to an RCT. The announcement described the trial design (60 patients) comparing optimized multichannel tDCS, conventional tDCS and sham for major depression, positioning Neuroelectrics in clinical-trial activity in 2025.

Modalities Covered:

  • Cognitive Behavioral Therapy (CBT)
  • Mindfulness-Based Stress Reduction (MBSR)
  • Biofeedback
  • Neurofeedback
  • Transcranial Magnetic Stimulation (TMS)
  • Other Modalities

Mechanism of Actions Covered:

  • Neuroplasticity Enhancement
  • Autonomic Nervous System Regulation
  • Hormonal Modulation
  • Immune System Modulation
  • Pain Pathway Interruption
  • Other Mechanisms

Delivery Modes Covered:

  • In-Person Therapy
  • Digital Therapeutics
  • Wearable Devices
  • Remote Monitoring Platforms
  • Other Delivery Modes

Distribution Channels Covered:

  • Direct Sales
  • Distributors
  • Online Platforms
  • Other Channels

Applications Covered:

  • Chronic Pain Management
  • Mental Health Disorders
  • Neurological Rehabilitation
  • Sleep Disorders
  • Cardiovascular Regulation
  • Other Applications

End Users Covered:

  • Hospitals
  • Specialty Clinics
  • Rehabilitation Centers
  • Homecare Settings
  • Academic & Research Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Non-Pharmacologic Modulators Market, By Modality

  • 5.1 Introduction
  • 5.2 Cognitive Behavioral Therapy (CBT)
  • 5.3 Mindfulness-Based Stress Reduction (MBSR)
  • 5.4 Biofeedback
  • 5.5 Neurofeedback
  • 5.6 Transcranial Magnetic Stimulation (TMS)
  • 5.7 Other Modalities

6 Global Non-Pharmacologic Modulators Market, By Mechanism of Action

  • 6.1 Introduction
  • 6.2 Neuroplasticity Enhancement
  • 6.3 Autonomic Nervous System Regulation
  • 6.4 Hormonal Modulation
  • 6.5 Immune System Modulation
  • 6.6 Pain Pathway Interruption
  • 6.7 Other Mechanisms

7 Global Non-Pharmacologic Modulators Market, By Delivery Mode

  • 7.1 Introduction
  • 7.2 In-Person Therapy
  • 7.3 Digital Therapeutics
  • 7.4 Wearable Devices
  • 7.5 Remote Monitoring Platforms
  • 7.6 Other Delivery Modes

8 Global Non-Pharmacologic Modulators Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Direct Sales
  • 8.3 Distributors
  • 8.4 Online Platforms
  • 8.5 Other Channels

9 Global Non-Pharmacologic Modulators Market, By Application

  • 9.1 Introduction
  • 9.2 Chronic Pain Management
  • 9.3 Mental Health Disorders
  • 9.4 Neurological Rehabilitation
  • 9.5 Sleep Disorders
  • 9.6 Cardiovascular Regulation
  • 9.7 Other Applications

10 Global Non-Pharmacologic Modulators Market, By End User

  • 10.1 Introduction
  • 10.2 Hospitals
  • 10.3 Specialty Clinics
  • 10.4 Rehabilitation Centers
  • 10.5 Homecare Settings
  • 10.6 Academic & Research Institutes
  • 10.7 Other End Users

11 Global Non-Pharmacologic Modulators Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Neuroelectrics
  • 13.2 Flow Neuroscience
  • 13.3 Happify Health
  • 13.4 Pear Therapeutics
  • 13.5 Fisher Wallace Laboratories
  • 13.6 NeuroSky
  • 13.7 MindMaze
  • 13.8 Omada Health
  • 13.9 Better Therapeutics
  • 13.10 BehaVR
  • 13.11 Neurovalens
  • 13.12 NeuroSigma
  • 13.13 Cognifisense
  • 13.14 NeuroTherapeutics Pharma
  • 13.15 NeuroMetrix
  • 13.16 Theranica

List of Tables

  • Table 1 Global Non-Pharmacologic Modulators Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Non-Pharmacologic Modulators Market Outlook, By Modality (2024-2032) ($MN)
  • Table 3 Global Non-Pharmacologic Modulators Market Outlook, By Cognitive Behavioral Therapy (CBT) (2024-2032) ($MN)
  • Table 4 Global Non-Pharmacologic Modulators Market Outlook, By Mindfulness-Based Stress Reduction (MBSR) (2024-2032) ($MN)
  • Table 5 Global Non-Pharmacologic Modulators Market Outlook, By Biofeedback (2024-2032) ($MN)
  • Table 6 Global Non-Pharmacologic Modulators Market Outlook, By Neurofeedback (2024-2032) ($MN)
  • Table 7 Global Non-Pharmacologic Modulators Market Outlook, By Transcranial Magnetic Stimulation (TMS) (2024-2032) ($MN)
  • Table 8 Global Non-Pharmacologic Modulators Market Outlook, By Other Modalities (2024-2032) ($MN)
  • Table 9 Global Non-Pharmacologic Modulators Market Outlook, By Mechanism of Action (2024-2032) ($MN)
  • Table 10 Global Non-Pharmacologic Modulators Market Outlook, By Neuroplasticity Enhancement (2024-2032) ($MN)
  • Table 11 Global Non-Pharmacologic Modulators Market Outlook, By Autonomic Nervous System Regulation (2024-2032) ($MN)
  • Table 12 Global Non-Pharmacologic Modulators Market Outlook, By Hormonal Modulation (2024-2032) ($MN)
  • Table 13 Global Non-Pharmacologic Modulators Market Outlook, By Immune System Modulation (2024-2032) ($MN)
  • Table 14 Global Non-Pharmacologic Modulators Market Outlook, By Pain Pathway Interruption (2024-2032) ($MN)
  • Table 15 Global Non-Pharmacologic Modulators Market Outlook, By Other Mechanisms (2024-2032) ($MN)
  • Table 16 Global Non-Pharmacologic Modulators Market Outlook, By Delivery Mode (2024-2032) ($MN)
  • Table 17 Global Non-Pharmacologic Modulators Market Outlook, By In-Person Therapy (2024-2032) ($MN)
  • Table 18 Global Non-Pharmacologic Modulators Market Outlook, By Digital Therapeutics (2024-2032) ($MN)
  • Table 19 Global Non-Pharmacologic Modulators Market Outlook, By Wearable Devices (2024-2032) ($MN)
  • Table 20 Global Non-Pharmacologic Modulators Market Outlook, By Remote Monitoring Platforms (2024-2032) ($MN)
  • Table 21 Global Non-Pharmacologic Modulators Market Outlook, By Other Delivery Modes (2024-2032) ($MN)
  • Table 22 Global Non-Pharmacologic Modulators Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 23 Global Non-Pharmacologic Modulators Market Outlook, By Direct Sales (2024-2032) ($MN)
  • Table 24 Global Non-Pharmacologic Modulators Market Outlook, By Distributors (2024-2032) ($MN)
  • Table 25 Global Non-Pharmacologic Modulators Market Outlook, By Online Platforms (2024-2032) ($MN)
  • Table 26 Global Non-Pharmacologic Modulators Market Outlook, By Other Channels (2024-2032) ($MN)
  • Table 27 Global Non-Pharmacologic Modulators Market Outlook, By Application (2024-2032) ($MN)
  • Table 28 Global Non-Pharmacologic Modulators Market Outlook, By Chronic Pain Management (2024-2032) ($MN)
  • Table 29 Global Non-Pharmacologic Modulators Market Outlook, By Mental Health Disorders (2024-2032) ($MN)
  • Table 30 Global Non-Pharmacologic Modulators Market Outlook, By Neurological Rehabilitation (2024-2032) ($MN)
  • Table 31 Global Non-Pharmacologic Modulators Market Outlook, By Sleep Disorders (2024-2032) ($MN)
  • Table 32 Global Non-Pharmacologic Modulators Market Outlook, By Cardiovascular Regulation (2024-2032) ($MN)
  • Table 33 Global Non-Pharmacologic Modulators Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 34 Global Non-Pharmacologic Modulators Market Outlook, By End User (2024-2032) ($MN)
  • Table 35 Global Non-Pharmacologic Modulators Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 36 Global Non-Pharmacologic Modulators Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 37 Global Non-Pharmacologic Modulators Market Outlook, By Rehabilitation Centers (2024-2032) ($MN)
  • Table 38 Global Non-Pharmacologic Modulators Market Outlook, By Homecare Settings (2024-2032) ($MN)
  • Table 39 Global Non-Pharmacologic Modulators Market Outlook, By Academic & Research Institutes (2024-2032) ($MN)
  • Table 40 Global Non-Pharmacologic Modulators Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.